Erratum: Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: A systematic review and meta-analysis(Scientific Reports 5(8191) 10.1038/srep08191);Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: A systematic review and meta-analysis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Lai, Tianwen ^a,b   Wang, Shaobin ^a   Xu, Zhiwei ^a   Zhang, Chao ^a   Zhao, Yun ^a   Hu, Yue ^a   Cao, Chao ^a   Ying, Songmin ^a,d   Chen, Zhihua ^a   Li, Wen ^a   Wu, Bin ^b   Shen, Huahao ^a,c  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Affiliated Hospital   (China)

^c State Key Laboratory of Respiratory Disease   (China)

^d ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; OMALIZUMAB;

AGE; ASTHMA; CLINICAL TRIAL (TOPIC); FACTUAL DATABASE; HUMAN; META ANALYSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGE FACTORS; ANTI-ALLERGIC AGENTS; ASTHMA; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; HUMANS; OMALIZUMAB; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84942862413     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09548     Document Type: Erratum

References (69)

1. Peters, S. P. et al. Real-world evaluation of asthma control and treatment (REACT): findings from a national web-based survey. J Allergy Clin Immunol 119, 1454-1461 (2007).
2. Rijavec, M., Korosec, P., Zavbi, M., Kern, I., Malovrh, M. M. Let-7a is differentially expressed in bronchial biopsies of patients with severe asthma. Sci Rep 4, 6103 (2014).
3. Bardelas, J., Figliomeni, M., Kianifard, F., Meng, X. A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Omalizumab on Asthma Control in Patients with Persistent Allergic Asthma. J Asthma 49, 144-152 (2012).
4. Ayres, J. G. et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 59, 701-708 (2004).
5. Buhl, R. et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 20, 1088-1094 (2002).
6. Luskin, A. T., Kosinski, M., Bresnahan, B.W., Ashby, M., Wong, D. A. Symptom control and improved functioning: the effect of omalizumab on asthma-related quality of life (ARQL). J Asthma 42, 823-827 (2005).
7. Karpel, J. et al. Effectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthma. Ann Allergy Asthma Immunol 105, 465-470 (2010).
8. Kulus, M. et al. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Curr Med Res Opin 26, 1285-1293 (2010).
9. National Heart Lung and Blood Institute, Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. ,http://www.nhlbi.nih.gov/health-pro/guidelines/current/asthmaguidelines/summary-report-2007.htm. (2007) Date of access: 20/05/2014.
10. Noga, O., Hanf, G., Kunkel, G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 131, 46-52 (2003).
11. Berger, W., Gupta, N.,McAlary, M., Fowler-Taylor, A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 91, 182-188 (2003).
12. Silkoff, P. E., Romero, F. A., Gupta, N., Townley, R. G., Milgrom, H. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), amonoclonal anti-immunoglobulin E antibody. Pediatrics 113, e308-12 (2004).
13. Platts-Mills, T. A. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 164, S1-5 (2001).
14. Bousquet, J. et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 125, 1378-1386 (2004).
15. Hochhaus, G. et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 19, 491-498 (2003).
16. Normansell, R.,Walker, S., Milan, S. J., Walters, E. H., Nair, P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 13, 1, CD003559 (2014).
17. Chipps, B. E., Figliomeni, M., Spector, S. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma. Allergy Asthma Proc 33, 377-385 (2012).
18. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. ,http://www.ncbi.nlm. nih.gov/books/NBK7232/. (2007) Date of access: 20/07/2014.
19. Vieira, T., de Oliveira, J. F., da Gracą Castel-Branco, M. Short and long-term quality of life and asthma control with omalizumab therapy in a real life setting in Portugal. Allergol Immunopathol (Madr) 42, 3-10 (2014).
20. Walker, S., Monteil, M., Phelan, K., Lasserson, T. J.,Walters, E. H. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 19, CD003559 (2006).
21. Corren, J. et al. Safety and tolerability of omalizumab. Clin Esp Allergy 39, 788-797 (2009).
22. Rodrigo, G. J., Neffen, H., Castro-Rodriguez, J. A. Efficacy and safety of subcutaneous omalizumab vs Placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 139, 28-35 (2011).
23. Bardelas, J., Figliomeni, M., Kianifard, F., Meng, X. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma 49, 44-52 (2012).
24. Bousquet, J. et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 66, 671-678 (2011).
25. Busse, W. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108, 184-190 (2001).
26. Chanez, P. et al. Omalizumab-induced decrease of FcjRI expression in patients with severe allergic asthma. Respir Med 104, 1608-1617 (2010).
27. Hanania, N. A. et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 154, 573-582 (2011).
28. Holgate, S. T. et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 34, 632-638 (2004).
29. Hoshino, M., Ohtawa, J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration 83, 520-528 (2012).
30. Humbert, M. et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60, 309-316 (2005).
31. Kopp, M. V. et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 39, 271-279 (2009).
32. Lemanske, R. F. Jr. et al. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 110, e55 (2002).
33. Massanari, M., Kianifard, F., Zeldin, R. K., Geba, G. P. Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma. Allergy Asthma Proc 30, 534-539 (2009).
34. Massanari, M. et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 125, 383-389 (2010).
35. Milgrom, H. et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 108, E36 (2001).
36. Milgrom, H., Fowler-Taylor, A., Vidaurre, C. F., Jayawardene, S. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin 27, 163-169 (2011).
37. Ohta, K. et al. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. Respirology 14, 1156-1165 (2009).
38. Rubin, A. S. et al. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). J Asthma 49, 288-293 (2012).
39. Siergiejko, Z. et al. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Curr Med Res Opin 27, 2223-2228 (2011).
40. Solèr, M. et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18, 254-261 (2001).
41. Vignola, A. M. et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 59, 709-717 (2004).
42. Zielen, S. et al. Omalizumab protects against allergen-induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma. Int Arch Allergy Immunol 160, 102-110 (2013).
43. Sullivan, S. D., Turk, F. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy 63, 670-684 (2008).
44. Finn, A. et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 111, 278-284 (2003).
45. Lanier, B. Q. et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 91, 154-159 (2003).
46. Niven, R., Chung, K. F., Panahloo, Z., Blogg, M., Ayre, G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med 102, 1371-1378 (2008).
47. Buhl, R. et al. Omalizumab provides long-term control in patients with moderateto-severe allergic asthma. Eur Respir J 20, 73-78 (2002).
48. Lanier, B. et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 124, 1210-1216 (2009).
49. Busse, W. W. et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 364, 1005-1015 (2011).
50. Brown, R., Turk, F., Dale, P., Bousquet, J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 62, 149-153 (2007).
51. Campbell, J. D., Spackman, D. E., Sullivan, S. D. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy 65, 1141-1148 (2010).
52. Dewilde, S., Turk, F., Tambour, M., Sandström, T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 22, 1765-1776 (2006).
53. Dal Negro, R. W., Pradelli, L., Tognella, S., Micheletto, C., Iannazzo, S. Costutility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol 43, 45-53 (2011).
54. van Nooten, F. et al. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. J Med Econ 16, 342-348 (2012).
55. Oba, Y., Salzman, G. A. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 114, 265-269 (2004).
56. Wu, A. C., Paltiel, A. D., Kuntz, K. M., Weiss, S. T., Fuhlbrigge, A. L. Costeffectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 20, 1146-1152 (2007).
57. Norman, G. et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess 17, 1-342 (2013).
58. Bousquet, J. et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 60, 302-308 (2005).
59. Bousquet, J. et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 101, 1483-1492 ( 2007).
60. Niebauer, K., Dewilde, S., Fox-Rushby, J., Revicki, D. A. Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol 96, 316-26 (2006).
61. Chipps, B. et al. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin 22, 2201-2208 (2006).
62. Owen, C. E. Anti-immunoglobulin E therapy for asthma. Pulm Pharmacol Ther 15, 417-424 (2002).
63. Lanier, B. Q. et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 91,154-159 (2003).
64. Li, Z., Begg, C. B. Random Effects Models for Combining Results from Controlled and Uncontrolled Studies in a Meta-Analysis. American Statistical Association 89, 1523-1527 (1994).
65. Dale, K. M., Coleman, C., Henyan, N. N., Kluger, J., White, C. M. Statins and cancer risk: a meta-analysis. JAMA 295, 74-80 (2006).
66. Phung, O. J., Makanji, S. S., White, C. M., Coleman, C. I. Almonds have a neutral effect on serum lipid profiles: a meta-analysis of randomized trials. J Am Diet Assoc 109, 865-873 (2009).
67. Liberati, A. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151, W65-W94 (2009).
68. Higgins, J. P., Thompson, S. G., Deeks, J. J., Altman, D. G. Measuring inconsistency in meta-analyses. BMJ 327, 557-560 (2003).
69. Egger, M., Davey Smith, G., Schneider, M., Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629-634 (1997).